CareSens N 30G lancets x 100

Product Information

Pioglitazone should not be used in people who have heart failure or who are at higher risk of fracture. Continue Pioglitazone therapy only if there is a reduction of ≥0.5 percentage points in HbA1c in 6 months. Monitor for liver toxicity. There is risk of bladder cancer with pioglitazone. Do not use in active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Assess risks for bladder cancer after 3-6months of starting pioglitazone. Refer to current BNF for full contraindications and interactions When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes For the treatment of patients with Type 2 diabetes who have nocturnal / severe hypoglycaemia or those with recurrent hypoglycaemic episodes requiring hospital admission NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

The managed introduction of biosimilar Insulin Glargine (Semglee®▼) for patients with Type 2 Diabetes Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines , under Guidance on Prescribing ; manufacturer advises to record the brand name and batch number after each administration. See DMMAG Type 2 Diabetes Mellitus - Guideline for the choice of oral and non-insulin antidiabetic agents for adults Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.for treating chronic heart failure with reduced ejection fraction as per NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction Transfer to prescribing to Primary Care should not happen until specialists can demonstrate a reduction in nocturnal hypoglycaemia(e.g. after 3-4 months) Type 2 Diabetes Mellitus: Guideline for the choice of oral and non-insulin antidiabetic agents for adults (May 2021) Victoza (liraglutide) 1.2mg daily dose is appropriate for most patients . Victoza 1.8mg daily is NON-FORMULARY. Patients requiring doses higher than Victoza (liraglutide) 1.2mg should be switched to an alternative GLP-1 receptor agonist e.g. Trulicity (dulaglutide) 1.5 mg weekly or Ozempic (semaglutide) 1mg weekly.

It should be swallowed whole with a sip of water (up to half a glass of water equivalent to 120 ml). THIS IS FOR DIABETES ONLY . Prescribe by brand (Victoza ® ) to avoid patients inadvertently receiving a different product licensed for obesity. Medicines suitable for routine use within primary care. Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians. For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar. There will no longer be a requirement to complete Blueteq forms for initiation or continuation of Freestyle Libre by specialist diabetes teams. Refer to BCWB CCG memo (1st October 2021)For your patients with diabetes who are currently prescribed Toujeo® SoloStar: A guide on how to use Toujeo ® SoloStar. Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

The CareSens N blood glucose monitor is designed to be easy to use; requiring only a small sample of blood, no coding required for the test strips and an easy to read display screen. MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis You can use blood samples taken your fingertip, palm or forearm. A small sample of blood is required and your result is displayed in less than 5 seconds. Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist. Using the latest technology, CareSens N monitors use a highly specific glucose oxidase reagent that will only measure glucose.For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A guide on how to use Toujeo® DoubleStar. For your patients with diabetes who are currently prescribed Apidra®: A guide on how to use Apidra®. The CareSens N meets and exceeds the 2013 ISO standards for blood glucose meter accuracy with 99% of results meeting the 2013 accuracy criteria. Sample loading – avoid spoiled tests

MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetesMeter is restricted for use in people with needle phobia, paediatrics, visual impairments and physical impairments requiring single-handed use For usein pregnant women with either gestational diabetes or pre-existing diabetes, after other insulins have been tried and failed to reach post-prandial glucose targets. Patients are required to wait at least 30 minutes before eating/drinking or taking other oral medicinal products. Waiting less than 30 minutes decreases absorption. The CareSens N Blood Glucose Monitor offers easy and accurate testing and there’s no coding required. The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management servicewith a commercial agreement in place.